Thursday, March 17, 2011

Dezoner Dvd Sony Sr 200p

SINVACOR 40mg

SIMVASTATIN Active Group
modified substances therapeutic lipids, unbound
Product Type DRUG-FREE NHS scheme ETHICS FOR DISEASE
Class A Recipe Type RR - Repeat
Form Farm. COATED TABLETS BLISTER Container Data Commerc
valid for 24 months. 20/10/2004 Price
ATC C10AA01
The product contains no gluten gluten
Manufacturer Merck Sharp & Dohme SpA



NAME
SINVACOR COATED TABLETS FILM

Pharmacotherapeutic
HMG-CoA reductase.

ACTIVE
Each tablet contains 10 mg of simvastatin.
Each tablet contains 20 mg of simvastatin. Each tablet contains 40 mg of simvastatin.
Excipient (s): For a full list of excipients, see Section 6.1
clip.

EXCIPIENTS
film-coated tablets of 10 mg and 20 mg lactose monohydrate, bu
tilidrossianisolo, ascorbic acid, citric acid monohydrate, microcrystalline cellulose
to, pregelatinized starch, magnesium stearate, ipromel
losa, hydroxypropyl cellulose, titanium dioxide, talc , iron oxide already at
, red iron oxide. Film-coated tablets 40 mg: lacto
sio monohydrate, butylated hydroxyanisole, ascorbic acid, citric acid mo
noidrato, microcrystalline cellulose, pregelatinized starch, magnesium stearate
, hypromellose, hydroxypropyl cellulose, titanium dioxide, talc or
, red iron oxide. INDICATIONS


Hypercholesterolemia; treatment of primary hypercholesterolemia or mixed dyslipidemia de
lla, as an adjunct to diet when the TA said
to diet and other non-pharmacological treatments and 'inadequate;
treatment of homozygous familial hypercholesterolemia as integrat
hours diet and other lipid-lowering treatments or if such negotiable
catkins are not appropriate; prevention of cardiovascular disease mortality reduction
'and morbidity' cardiovascular disease in patients with TIA
atherosclerotic cardiovascular disease or diabetes mellitus, LEVEL OF
with normal or increased cholesterol, as a carrier for cor rection
other risk factors and other therapies cardioprotettiv
e.

CONTRAINDICATIONS / EFF.SECONDAR
hypersensitivity 'to simvastatin or to any of the excipients
; Active liver disease or persistent elevations of serum transamination
asi no obvious cause, pregnancy and lactation; somminis
traction concomitant potent inhibitors of CYP3A4.


DOSAGE The dosage range and '5-80 mg / day given orally
single dose in the evening. Dosage adjustments, if required,
should be made at intervals of not less than 4 weeks
up to a maximum of 80 mg / day administered as a single dose in the evening. The
the dose of 80 mg and 'only recommended in patients with severe ipercolester
Olema and high risk of cardiovascular complications. Iperc
olesterolemia The patient should be placed on a standardized diet of cholesterol-lowering
and should continue on this diet during
treatm ent with the medicine. The starting dose and 'habitually
of 10-20 mg / day administered single dose in the evening. Patients for whom
and 'require a large reduction in LDL-C (more than 45%)
I can not begin with 20-40 mg / day given in single dose in the evening.
Adjustments of dosage, if required, should be carried out c ome
specified above. On the ba
homozygous familial hypercholesterolemia if the results of a controlled clinical trial, the dose recom
gone and '40 mg / day in the evening or 80 mg / day in three divided doses of 20
mg, 20 mg, and a dose to evening of 40 mg. In these patients, doctors
tion must be used in addition to other treatments ipolipemi
zzanti (eg. LDL apheresis) or if such treatments are not AVAILABLE
ill. Cardiovascular Prevention: The usual dose is'
20 to 40 m g / day given in single dose in the evening in patients at high risk of hio
coronary heart disease (CHD, with or without hyperlipidaemia). The ter
apia pharmacology can 'be started simultaneously with diet and physical
ll'esercizio. Adjustments of dosage, if required, must be
ono made as specified above. Concomitant therapy: the f
armaco and 'effective alone or in combination with
of bile acid sequestrants. Administration should be or> 2 hours before or> 4 or
and after administration of a bile acid sequestrant. For patients taking
cyclosporine, danazol, gemfibrozil, or other
fibrates (except fenofibrate) in connection to the drug, the dosage of the medicine I
should not exceed 10 mg / day. In patients taking amiodarone or verapamil
Ono in conjunction with drug dosage
product should not exceed 20 mg / day. Dosage in renal nell'insufficienz
: not required dosage in patients on c
moderate renal impairment.
in patients with renal impairment (creatinine clearance < 30 ml/ min), dosaggi superiori a
10 mg / day should be carefully assessed and, if deemed necessary
administered with caution. Use in the elderly are not required Agios
ustamenti assay. Use in children and adolescents: the experiment
nza in children and 'limited. The famraco not '
recommended for use in children.


STORAGE Store below 30 degrees C.

WARNINGS
Simvastatin may 'occasionally cause myopathy.
myopathy is sometimes expressed as rhabdomyolysis with or without renal failure secondary to myoglobinuria in
cuta and are rarely checked and
ffetti fatal. The risk of myopathy and 'increased by high levels of activity
' inhibition of HMG-CoA reductase inhibitory activity in plasma.
The risk of myopathy / rhabdomyolysis and 'dose related. Measurement of creatine kinase level
them: not measure after strenuous exercise or in the presence of any
za alternative cause of CK increase because that would 'rend
and difficult to interpret the data. If CK levels are significantly elevated at baseline
Icatian these should be re-tested after 5-7 days
to confirm the results. Before treatment:
you inform patients starting therapy with simvastatin or
or increase the dose of the same, the risk of myopathy and told to report immed
iatamente any type of pain, tenderness' or the unexplained muscle weakness
. Statins should be prescribed with caution in p
those companies with predisposing factors for rhabdomyolysis. Measure the liv
ello CK before starting treatment in the following cases.
elderly (age '> 70 years) renal dysfunction, hypothyroidism, uncontrolled
personal or family history of hereditary muscular disorders;
presence of toxicity in previous episodes of' muscle with a statin or
fi anced, alcohol abuse. In such situations, the risk that the treatment involves
to be assessed in relation to possible benefit, and
d in case of treatment is recommended close monitoring of paz
othing. If the patient had a history of muscle disorders
during treatment with a fibrate or a statin, including
TREA with a different member of the class must I know it
be initiated with caution. If CK levels are significantly elevated at baseline
not begin treatment. If during treatment with stat
ine the patient reported the appearance of tenderness', cr
large muscle weakness or without apparent cause, it is necessary to measure the levels of CK
. In the case of significantly higher levels of CK in the absence of intense physical and
financial year, discontinue therapy. Stop the treatment if treated
muscular symptoms are severe and cause daily discomfort
or, even if CK levels are \u0026lt;5 times the upper limit of normal sup
eriore; stop treatment if myopathy is suspected for any other
reason. Only if symptoms resolve
SOEC and CK levels return to normality ', take into account
tion the reintroduction of the statin or introduction of a statin
alternative to more' low-dose and under close monitoring. TE
therapy with simvastatin should be temporarily stopped a few
days before elective major surgery and in the event of an outbreak of
any major medical or surgical condition. The
the risk of myopathy and rhabdomyolysis, and 'd
increased significantly with the concomitant use of simvastatin with potent inhibitors of CYP3A
4, and gemfibrozil, cyclosporine, and danazol. The risk of myopathy and rhabdomyolysis
and 'also increased by concomitant use of other fiber
you or by concomitant use of amiodarone or verapamil with doses
' high simvastatin. There 's also a slight increase in risk when diltiazem is used
simvastatin 80 mg. The
the risk of myopathy, including rhabdomyolysis, may 'be increased by co
ncomitante fusidic acid and statins. Consequently, regarding
CYP3A4 inhibitors, concomitant use of simvastatin with Itra
conazolo, ketoconazole, HIV protease inhibitors,
erythromycin, clarithromycin, telithromycin and nefazodone and 'contra-indicated.
If treatment with itraconazole, ketoconazole, erythromycin, claritromici
na or telithromycin is' unavoidable, therapy with simvastatin should be discontinued at
during treatment. In addition, we must act with caution and
when combining simvastatin with certain other inhibitors
the least potent CYP3A4: Cyclosporine, verapamil, diltiazem. The concomitant recruitment
tion of grapefruit juice and simvastatin should be avoided
nanny. The dose of simvastatin should not exceed 10 mg / day in paz
othing in concomitant therapy with cyclosporine, danazol, or gemfibrozi
l. The use in combination with gemfibrozil should be avoided unless ch
and benefits are likely to outweigh the increased risks of this drug combination
. The benefits of simvastatin
1 0 mg / day in combination with other fibrates (except fenofibrate), c
iclosporina or danazol should be carefully weighed against the potential risks of these associations
. We must act with caution
q hen fenofibrate or niacin (> 1 g / day) are prescribed with
to simvastatin, as both drugs can cause myopathy when given alone
. The concomitant use of simvastatin at doses higher than 20
mg daily with amiodarone or verapamil should be avoided
unless the clinical benefit is likely to outweigh the A
ument risk of myopathy. If the association is demonstrated need
ia, patients treated with fusidic acid and simvastatin should be
and placed under close monitoring. Consider the temporary interruption of treatment with simvastatin
nea. Hepatic Effects: In some pazie
nti adults occurred persistent increases in transaminases s
ieriche. When these patients in the simvastatin and '
been interrupted or suspended, the transaminase levels usually fell lentam
body pretreatment levels. It is recommended that tests of functionality
'liver before you start treatment and, in
to follow, as indicated by the clinical point of view. Patients for whom
and 'established a dose of 80 mg should be u n
undergo further testing prior to administration, three months after the start of
lla dosing of 80 mg, and thereafter every
p eriod for the first year of treatment.
special attention should be paid to patients who develop elevated serum levels of trans
Minasi, and in these patients, measurements should be repeated promptly and then performed
more 'frequently. If the level of transaminases
them show an increase in the simvastatin should they
king suspended. The product should be used with caution in patients who consume
amount 'of alcohol. Moderate increase in transaction
Minasi serum have been reported following treatment with SIMV
astatina. These changes appeared soon after the start of the TREA
with simvastatin, were often transient, is
you are not accompanied by any symptoms and not 'I was asked to
interruption of therapy. This product contains lactose.

INTERACTIONS
Pharmacodynamic interactions. The risk of myopathy, including rabdo
myolysis, is increased during the concomitant administration
you with fibrates and niacin (> 1 g / day). There 'a pharmacokinetic interaction with gemfibrozil
netic leads to increased plasma levels of simvastatin
. When simvastatin and fenofibrate are administered
you there and at the same 'evidence that the risk of myopathy s
uperiore the sum of the individual risks in each of the two drugs
. For other fibrates are not adequate data to
pharmacovigilance and pharmacokinetics. Pharmacokinetic interactions. V
order now for prescription drugs on the interagiscon
or simvastatin. Drug interactions associated with aum ento
risk of myopathy / rhabdomyolysis. Potent inhibitors of CYP3A
4: itraconazole, ketoconazole, erythromycin, clarithromycin, telitromi
China, HIV protease inhibitors, nefazodone: contraindicated co
n simvastatin. Gemfibrozil: avoid but in case of need 'treasuries
not support the 10 mg / day of simvastatin. Cyclosporine, danazol, other fiber
you (except fenofibrate): Do not exceed 10 mg / day of simvastatin. Am
iodarone, verapamil: Do not exceed 20 mg / day of simvastatin. Diltiazem
: Do not exceed 40 mg / day of simvastatin. Fusidic acid:
patients must be closely monitored. Can 'be
ata Consider the temporary interruption of treatment with simvastatin. Grapefruit juice
: avoid drinking grapefruit juice when taking simvas
Tatin. Potent inhibitors of cytochrome P450 3A4 increase the risk of myopathy and rhabdomyolysis
or increasing the concentration of active
ta 'of HMG-CoA reductase inhibitory activity in plasma during therapeutic
pious with simvastatin. Concomitant administration of itraconazole
resulted in an increase of more than more 'than 10 times the exposure to simvastatin acid
position. Telithromycin caused an
ent increments equal to 11 times the exposure to simvastatin acid. Therefore de
to the association with itraconazole, ketoconazole, inhibitors of HIV pro tease
, erythromycin, clarithromycin, telithromycin and nefazodo
it and 'contra-indicated. If treatment with itraconazole, ketoconazole
, erythromycin, clarithromycin or telithromycin is not 'unavoidable, you
therapy with simvastatin should be suspended during treatment.
Use caution when combining simvastatin with certain other inhibited
Itor less potent CYP3A4: Cyclosporine, verapamil, diltiazem.
The risk of myopathy / rhabdomyolysis and 'increased by a concomitant administration of cyclosporine
especially with doses' s high
imvastatina. The dose of simvastatin should not exceed
10 mg / day in patients receiving concomitant medication with cyclosporine. The
closporina there was shown to increase the AUC of HMG-Co A reductase
. The increase in AUC for simvastatin acid and 'presumibi
lment due, in part, to inhibition of CYP3A4. Danazol: The risk
I of myopathy and rhabdomyolysis, and 'increased by administration of danazol with conc
omitante doses' high of simvastatin. Gemfibrozi
l increases the AUC of simvastatin acid by 1.9-fold, possibly due to inhibition of
glucuronidation pathway.
verapamil and amiodarone: the risk of myopathy and rhabdomyolysis and 'know
dministration increased by concomitant use of amiodarone or verapamil with doses more' high
of simvastatin. In an ongoing clinical trial, and 'ta
myopathy was noted in 6% of patients treated with simvastatin 80 mg and love
odarone. An analysis of available clinical trials showed NCUs
idenza of myopathy by around 1% in patients treated with simvastati
na 40 mg or 80 mg and verapamil. In a pharmacokinetic study, concomitant administration with the sum
verapamil resulted in an increase
or equal to 2.3 times the exposure to simvastatin acid, presumably
mind because, in part, to inhibition of CYP3A4. The dosage is
mvastatina should not exceed 20 mg / day for patients in therapeutic
pious concomitant amiodarone or verapamil, unless the benefit
c lin is likely to outweigh the increased risk of my
pathy and rhabdomyolysis. Diltiazem: e 'was shown an incidence of 1%
myopathy in patients treated with simvastatin 80 mg and dilti
Azem. The risk of myopathy in patients taking simvastatin 40 mg and
'was increased by concomitant diltiazem.
The concomitant administration of diltiazem caused an increase of 2
, 7 times the exposure to simvastatin acid. The dosage of SIMV
astatina should not exceed 40 mg / day in patients with concomitant diltiazem
, unless the clinical benefit is s
uperiore increased risk of myopathy and rhabdomyolysis. Fus
idic acid: The risk of myopathy may 'be increased by concomitant
nte of fusidic acid and statins. With simvastatin were reposition
D TO isolated cases of rhabdomyolysis. Can 'be considered a Fail
ion temporary treatment with simvastatin.
If the combination proves necessary, patients treated with fusidic acid and simvast
atina must be closely monitored. Grapefruit juice
mo: inhibits cytochrome P450 3A4. The concomitant use of statin and SIMV
large amounts' of grapefruit juice resulted in an increase
chin 7 times the exposure to simvastatin acid. Even as
intake of 240 ml of grapefruit juice in the morning and simvastatin in the evening
resulted in an increase of 1.9 times. Simvastatin has not
an inhibitory effect on cytochrome P450 3A4. Oral anticoagulants: n
the two trials, one in normal volunteers and the other in patients
ercolesterolemici ip, simvastatin 20-40 mg / day had a modest ef fect
enhancement of coumarin anticoagulants: the time of pr
otrombina reported as International Normalized Ratio (INR) and 'increased
Committee from a baseline of 1.7 to 1.8 and from a baseline of 2.6 to 3.4 in the voluntary re
and patient studies, respectively. There have been reports of very rare cas
the elevated INR. In patients taking coumarin anticoagulants
, the prothrombin time should be determined before the
niziare treatment with simvastatin and frequently enough they
the course of early therapy to ensure that the experience
s no significant alteration of prothrombin time.
Once documented a stable prothrombin time, thrombin time pro
can be monitored at the intervals recommended accustomed
lment for patients on coumarin anticoagulants. If the
dose of simvastatin is changed or discontinued, must repeat the same procedure
king. Simvastatin therapy has not 'been
ociata ass with bleeding or with changes in prothrombin time in pa
patients not taking anticoagulants.

SIDE EFFECTS
The frequencies of the following adverse events, reported during
s Tubes clinical and / or post-marketing use, are classified on the
basis of the evaluation of their incidence rates in large, long-term clinical studies
placebo-controlled trials, including HPS and 4S
with 20,536 and 4,444 patients respectively. For the HPS were r ed trademarks
only serious adverse events as well as myalgia, increases in serum
nsaminasi and CK. For the 4S were recorded them all g
adverse events listed below. If the incidence rates on
simvastatin were less than or similar to that for the
plac ebo in these studies, and there were reports of spontaneous events reasonably
reasonably be classified as related to causation ', q
Standard grease adverse events were classified as "Rare". In HPS on
Sinvacor 20,536 patients treated with 40 mg / day (n = 10,269)
or placebo (n = 10,267), the safety profiles were comparable between patients treated with
Sinvacor 40 mg and placebo n
and 5-year average duration of the study. Discontinuation rates of tr
attamento due to side effects were comparable (4
, 8% in patients treated with Sinvacor 40 mg compared with 5.1% in pts
othing treated with placebo). The incidence of myopathy and 'was inferior
and 0.1% in patients treated with 40 mg Sinvacor. There were the
ivelli Elevated transaminases (> 3 times the upper super
iore accordance with the confirmation by repeat test) occurred in 0.21% (
n = 21) of patients treated with 40 mg Sinvacor
compared with 0.09% (n = 9) of patients treated with placebo. The frequencies of events to
ctions are ranked according to the following: Very common (> 1 / 1
0), common (> = 1 / 100, 1/1.000 = < 1/10), non comune (>, < 1/100), raro
(> = 1/10.000, < 1/1.000), molto raro (< 1/10.000) incluse segnalazioni
isolated. Blood and lymphatic disorders. Rare: anemia. Patola
gie the nervous system. Rare: headache, paresthesia, dizziness, peripheral neuropathy
ia. Gastrointestinal disorders. Rare: constipation, abdominal
inal pain, bloating, dyspepsia, diarrhea, nausea, vomiting , pancreatitis. Pa
hepatobiliary pathologies. Rare: hepatitis / jaundice, very rare: hepatic failure
. Skin and subcutaneous tissue. Rare: eruzio
it, pruritus, alopecia. System disorders muscoloscheletric
o connective tissue. Rare: myopathy, rhabdomyolysis, myalgia, muscle cra
mpi. General disorders and administration site
administration. Rare: asthenia. It 'been reported rarely app arent
hypersensitivity syndrome' that has included some of you by following
features: angioedema, lupus-like syndrome, polymyalgia rheumatic
matic, dermatomyositis, vasculitis, thrombocytopenia, eosinophilia, increased to
ESR, arthritis and arthralgia, urticaria, photosensitivity ', fever and
, flushing, dyspnea and malaise. Investigations. Rare:
and increases of serum transaminases (alanine aminotransferase, aspartate aminotran
ferase, gamma-glutamyl transpeptidase), increased alkaline phosphatase
ina; increased levels of serum CK.

PREGNANCY AND LACTATION
The drug 'contraindicated during pregnancy.
safety in pregnant women has not 'been established. S have not been conducted controlled clinical
Tubes with simvastatin in pregnant women. S ono
been received Rare reports of congenital anomalies following intrauterine exposure of the
to HMG-CoA reductase. Tut
However, in an analysis of approximately 200 prospectively followed pregnancies exposed duran
you in the first quarter to the drug or another inhibitor of HMG-CoA reductase
closely related, the incidence of congenital anomalies and
'comparable to that observed
in the general population. This number of pregnancies and '
was statistically sufficient to exclude an increase in congenital anomalies of 2.5 times or super
iore over the background. Although there is any highlighting
that the incidence of congenital abnormalities in offspring of patients tr
attati with the drug or other HMG-CoA reductase inhibitor treatment closely
Related differs from that observed in January
eral population, maternal treatment with this medicine may 'shrink in f
eto levels of mevalonate, a precursor of the biosynthesis of coles
terol. Atherosclerosis and 'a chronic process, and ordinarily breakers
uction of lipid-lowering drugs during pregnancy should
and have a limited impact on long-term risk associated with the ipe
rcolesterolemia primary. For these reasons, the medicine should not
tory and used in pregnant women who wish to become pregnant or know
accrue a state of pregnancy. Treatment with the drug should
tory and suspended for the duration of pregnancy or until it is stat
or determined that the woman is not 'in pregnancy. It 's not known whether sim
vastatina or its metabolites are excreted in breast milk. Since
and 'many drugs are excreted in human milk and because of' could
or cause serious adverse effects, women taking the medicin
ale should not breastfeed.

0 comments:

Post a Comment